Stay updated on Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial

Sign up to get notified when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    A site-wide NIH notice about terminology changes during a federal transition was removed from the page.
    Difference
    1%
    Check dated 2026-11-07T11:50:00.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T12:37:01.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    An NIH banner announces a website transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T12:15:44.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The site revision label in the footer changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T14:02:41.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer now identifies the site revision as v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T13:58:36.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record, with the standard site header and footer visible; this indicates access is blocked to the study page rather than an update to the study information.
    Difference
    0.5%
    Check dated 2026-09-26T18:44:36.000Z thumbnail image

Stay in the know with updates to Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.